Akorn, Inc. (AMEX: AKN) today announced the positive results of a Phase III pivotal trial for Akten�. The clinical trial was a randomized, placebo controlled, multi-centered, 4-arm trial in 209 subjects. The primary efficacy end point for achieving ocular anesthesia (p
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
éŽåŽ» 株価ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 6 2024 ã¾ã§ 7 2024 Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Productã®ãƒãƒ£ãƒ¼ãƒˆã‚’ã‚‚ã£ã¨è¦‹ã‚‹ã«ã¯ã“ã¡ã‚‰ã‚’クリック
Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
éŽåŽ» 株価ãƒãƒ£ãƒ¼ãƒˆ
ã‹ã‚‰ 7 2023 ã¾ã§ 7 2024 Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Productã®ãƒãƒ£ãƒ¼ãƒˆã‚’ã‚‚ã£ã¨è¦‹ã‚‹ã«ã¯ã“ã¡ã‚‰ã‚’クリック